X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs VENUS REMEDIES - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD VENUS REMEDIES ALEMBIC LTD/
VENUS REMEDIES
 
P/E (TTM) x 54.7 -1.5 - View Chart
P/BV x 2.2 0.1 2,078.3% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 ALEMBIC LTD   VENUS REMEDIES
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
VENUS REMEDIES
Mar-18
ALEMBIC LTD/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs72126 57.2%   
Low Rs3461 55.5%   
Sales per share (Unadj.) Rs4.7301.8 1.6%  
Earnings per share (Unadj.) Rs6.1-24.9 -24.5%  
Cash flow per share (Unadj.) Rs6.22.5 245.4%  
Dividends per share (Unadj.) Rs0.200-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs40.7293.3 13.9%  
Shares outstanding (eoy) m267.0312.34 2,163.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.30.3 3,635.9%   
Avg P/E ratio x8.7-3.8 -230.8%  
P/CF ratio (eoy) x8.536.7 23.1%  
Price / Book Value ratio x1.30.3 408.5%  
Dividend payout %3.30-   
Avg Mkt Cap Rs m14,1391,154 1,225.5%   
No. of employees `000NA0.9 0.0%   
Total wages/salary Rs m207393 52.8%   
Avg. sales/employee Rs ThNM4,026.1-  
Avg. wages/employee Rs ThNM425.0-  
Avg. net profit/employee Rs ThNM-331.8-  
INCOME DATA
Net Sales Rs m1,2553,724 33.7%  
Other income Rs m37023 1,645.3%   
Total revenues Rs m1,6253,747 43.4%   
Gross profit Rs m111395 28.1%  
Depreciation Rs m38338 11.2%   
Interest Rs m2354 0.5%   
Profit before tax Rs m442-275 -160.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2432 75.8%   
Profit after tax Rs m1,630-307 -531.1%  
Gross profit margin %8.910.6 83.5%  
Effective tax rate %5.4-11.5 -47.2%   
Net profit margin %129.8-8.2 -1,575.6%  
BALANCE SHEET DATA
Current assets Rs m1,8672,638 70.8%   
Current liabilities Rs m5912,305 25.7%   
Net working cap to sales %101.68.9 1,136.7%  
Current ratio x3.21.1 275.9%  
Inventory Days Days94135 69.6%  
Debtors Days Days7446 158.7%  
Net fixed assets Rs m1,7914,871 36.8%   
Share capital Rs m534123 432.8%   
"Free" reserves Rs m10,3243,496 295.3%   
Net worth Rs m10,8583,619 300.0%   
Long term debt Rs m411,374 3.0%   
Total assets Rs m11,5917,509 154.4%  
Interest coverage x260.90.2 117,000.8%   
Debt to equity ratio x00.4 1.0%  
Sales to assets ratio x0.10.5 21.8%   
Return on assets %14.10.6 2,229.8%  
Return on equity %15.0-8.5 -177.0%  
Return on capital %15.21.6 960.1%  
Exports to sales %1.50-   
Imports to sales %21.013.9 151.3%   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263517 51.0%   
Fx inflow Rs m190-   
Fx outflow Rs m264517 51.1%   
Net fx Rs m-244-517 47.3%   
CASH FLOW
From Operations Rs m236514 45.8%  
From Investments Rs m-224-123 182.0%  
From Financial Activity Rs m-27-387 6.9%  
Net Cashflow Rs m-154 -352.4%  

Share Holding

Indian Promoters % 64.0 32.9 194.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.2 111.1%  
FIIs % 9.7 0.6 1,672.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 66.4 39.3%  
Shareholders   54,701 20,121 271.9%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare ALEMBIC LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex at New Highs, Jet Airways Suspends Operations - Your Inside Scoop of the Markets(Podcast)

Jet Airways, once India's largest private airline halted its operations indefinitely yesterday. The carrier flew its last scheduled flight from Amritsar to Mumbai yesterday.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

ALEMBIC LTD Announces Quarterly Results (3QFY19); Net Profit Down 41.9% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, ALEMBIC LTD has posted a net profit of Rs 32 m (down 41.9% YoY). Sales on the other hand came in at Rs 243 m (down 18.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

ALEMBIC LTD Announces Quarterly Results (2QFY19); Net Profit Up 4.0% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, ALEMBIC LTD has posted a net profit of Rs 294 m (up 4.0% YoY). Sales on the other hand came in at Rs 336 m (up 3.1% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Apr 18, 2019 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD 5-YR ANALYSIS

COMPARE ALEMBIC LTD WITH

MARKET STATS